Evaluation of Some Hormones Total Antioxidant Capacity and Malondialdehyde Levels in Polycystic Ovarian Syndrome Women attending the gynecology Clinic at Nnewi

Hormones, Total Antioxidant Capacity and Malondialdehyde Levels in Polycystic Ovarian Syndrome Women

  • Augustine Chinedu Ihim Department of Medical Laboratory Science, Faculty of Health Sciences and Technology, Nnamdi Azikiwe University, Awka Anambra, Nigeria; https://orcid.org/0000-0001-9991-0714
  • Charles Chinedum Onyenekwe Department of Medical Laboratory Science, Faculty of Health Sciences and Technology, Nnamdi Azikiwe University, Awka Anambra, Nigeria;
  • Nkiruka Nwamaka Eze Department of Medical Laboratory Science, Faculty of Health Sciences and Technology, Nnamdi Azikiwe University, Awka Anambra, Nigeria; https://orcid.org/0009-0008-4028-2205
  • Patrick Chinedu Obi Department of Internal Medicine, Federal University Teaching Hospital Owerri, Imo State, Nigeria. https://orcid.org/0000-0003-2218-9206
  • Nosakhare Osakue Department of Medical Laboratory Science, Faculty of Health Sciences and Technology, Nnamdi Azikiwe University, Awka Anambra, Nigeria; https://orcid.org/0000-0002-3964-5223
  • Joseph Chimezie Awalu Department of Medical Laboratory Science, Evangel Akaeze Ebonyi State, Nigeria https://orcid.org/0000-0001-9457-8249
  • Tochukwu Anthony Ikwelle Department of Medical Laboratory Science, Faculty of Health Sciences and Technology, Nnamdi Azikiwe University, Awka Anambra, Nigeria; https://orcid.org/0009-0007-0014-8637

Abstract

Polycystic ovarian syndrome (PCOS), marked by oxidative stress and hormonal imbalances, causes infertility, insulin resistance, and diverse health problems. It not only affects physical health but also can strain marriages and lead to divorce, posing a notable societal issue. The levels of hormones (Estradiol (E2), Dihydroepiandrosterone sulfate (DHEA), luteinizing hormone (LH), follicle-stimulating hormone (FSH), progesterone (PROG) Testosterone (TEST)), total antioxidant capacity (TAC) and Malondialdehyde (MDA) in PCOS Women attending the gynecology Clinic at Nnewi were investigated. This cross-sectional study had 45 participants with PCOS as a test group and 45 participants without PCOS as the control group between the ages of 18-50 recruited. All the biochemical parameters were determined by enzyme-linked immunoassay technique. Data was expressed as Mean ± standard deviation. The differences in parameters studied between the PCOS group (test) and the control group were evaluated using an independent t-test. Statistical significance was set at p-value < 0.05. Result showed significant higher differences in the mean serum levels of DHEA (87.40±65.90), LH (34.7±36.1), FSH (19.61±14.73) and Testosterone (3.04±1.36) in women with PCOS compared with the control (1.035±0.54),( 20.76±18.1), (13.2±10.19), and (3.04±1.36)(p< 0.05) respectively. A higher significant difference exists in the mean serum MDA values of the test group (women with PCOS compared with the control group(p<0.05). This study concluded that oxidative stress and hormone imbalance occurred among participants with PCOS attending the gynecology clinic of Nnamdi Azikiwe University Teaching Hospital in Nnewi. 


Keywords: PCOS, Estradiol, DHEA, luteinizing hormone, FSH, progesterone, Testosterone, TAC

Keywords: PCOS, Estradiol , DHEA , luteinizing hormone , FSH, progesterone, Testosterone, TAC

Downloads

Download data is not yet available.

Author Biographies

Augustine Chinedu Ihim, Department of Medical Laboratory Science, Faculty of Health Sciences and Technology, Nnamdi Azikiwe University, Awka Anambra, Nigeria;

Department of Medical Laboratory Science, Faculty of Health Sciences and Technology, Nnamdi Azikiwe University, Awka Anambra, Nigeria;

Charles Chinedum Onyenekwe, Department of Medical Laboratory Science, Faculty of Health Sciences and Technology, Nnamdi Azikiwe University, Awka Anambra, Nigeria;

Department of Medical Laboratory Science, Faculty of Health Sciences and Technology, Nnamdi Azikiwe University, Awka Anambra, Nigeria;

Nkiruka Nwamaka Eze, Department of Medical Laboratory Science, Faculty of Health Sciences and Technology, Nnamdi Azikiwe University, Awka Anambra, Nigeria;

Department of Medical Laboratory Science, Faculty of Health Sciences and Technology, Nnamdi Azikiwe University, Awka Anambra, Nigeria;

Patrick Chinedu Obi, Department of Internal Medicine, Federal University Teaching Hospital Owerri, Imo State, Nigeria.

Department of Internal Medicine, Federal University Teaching Hospital Owerri, Imo State, Nigeria.

Nosakhare Osakue, Department of Medical Laboratory Science, Faculty of Health Sciences and Technology, Nnamdi Azikiwe University, Awka Anambra, Nigeria;

Department of Medical Laboratory Science, Faculty of Health Sciences and Technology, Nnamdi Azikiwe University, Awka Anambra, Nigeria;

Joseph Chimezie Awalu, Department of Medical Laboratory Science, Evangel Akaeze Ebonyi State, Nigeria

Department of Medical Laboratory Science, Evangel Akaeze Ebonyi State, Nigeria

Tochukwu Anthony Ikwelle, Department of Medical Laboratory Science, Faculty of Health Sciences and Technology, Nnamdi Azikiwe University, Awka Anambra, Nigeria;

Department of Medical Laboratory Science, Faculty of Health Sciences and Technology, Nnamdi Azikiwe University, Awka Anambra, Nigeria;

References

1. Deans R, Polycystic ovary syndrome in adolescence. Medical Sciences. 2019 Oct 2;7(10):101. https://doi.org/10.3390/medsci7100101
2. Witchel SF, Oberfield SE, Peña AS. Polycystic ovary syndrome: pathophysiology, presentation, and treatment with emphasis on adolescent girls. Journal of the Endocrine Society. 2019 Aug;3(8):1545-73. https://doi.org/10.1210/js.2019-00078
3. Polycystic Ovary Syndrome. Available online: https://www.womenshealth.gov/a-z-topics/polycystic-ovary-syndrome (accessed on 22 September 2022).
4. Bednarska S, Siejka A. The pathogenesis and treatment of polycystic ovary syndrome: What’s new? Adv. Clin. Exp. Med. 2017, 26, 359–367. https://doi: 10.17219/acem/59380
5. Ganie MA. Vasudevan V. Wani IA, Baba MS, Arif T, Rashid A, Epidemiology, pathogenesis, genetics & management of polycystic ovary syndrome in India. Indian J. Med Res. 2019, 150, 333–344. https://doi: 10.4103/ijmr.IJMR_1937_17
6. Mohd M, Maqbool M, Dar MA, Mushtaq I, Polycystic ovary syndrome, a modern epidemic: an overview, Journal of Drug Delivery and Therapeutics. 2019;9(3):641-644 https://doi.org/10.22270/jddt.v9i1-s.2275
7. M Maqbool, MA Dar, I Gani, MI Geer, Insulin resistance and polycystic ovary syndrome: a review, Journal of drug delivery and therapeutics 2019;9(1-s):433-436. https://doi.org/10.22270/jddt.v9i1-s.2275
8. Eshre TR, Group AS-SPCW. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and sterility. 2004;81(1):19-25 https://doi.org/10.1093/humrep/deh098
9. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE and Witchel SF. Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. J Clin Endocrinol Metab. 2006;91(11):4237-4245. https://doi.org/10.1210/jc.2006-0178
10. Balen AH, Laven JSE, Tan SL and Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum reprod update. 2003;9(6):505-514. https://doi.org/10.1093/humupd/dmg044
11. Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. The American journal of medicine. 2001 Dec 1;111(8):607-13. https://doi.org/10.1016/S0002-9343(01)00948-2
12. Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, Lobo R, Norman RJ, Talbott E and Dumesic DA. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab. 2010;95(5):2038-2049. https://doi.org/10.1210/jc.2009-2724
13. Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. The American journal of medicine. 2001 Dec 1;111(8):607-13. https://doi.org/10.1016/S0002-9343(01)00948-2
14. Doroszewska K, Milewicz T, Mrozińska S, Janeczko J, Rokicki R, Janeczko M, Warzecha D, Marianowski P. Blood pressure in postmenopausal women with a history of polycystic ovary syndrome. Menopause Review/Przegląd Menopauzalny. 2019 Jun 14;18(2):94-8. https://doi.org/10.5114/pm.2019.84039
15. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. The journal of clinical endocrinology & metabolism. 1999 Jan 1;84(1):165-9. https://doi.org/10.1210/jcem.84.1.5393
16. Tasali E, Van Cauter E, Ehrmann DA. Polycystic ovary syndrome and obstructive sleep apnea. Sleep medicine clinics. 2008 Mar 1;3(1):37-46. https://doi.org/10.1016/j.jsmc.2007.11.001
17. Dumesic DA, Lobo RA. Cancer risk and PCOS. Steroids. 2013 Aug 1;78(8):782-5. https://doi.org/10.1016/j.steroids.2013.04.004
18. Boomsma CM, Eijkemans MJ, Hughes EG, Visser GH, Fauser BC, Macklon NS. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Human reproduction update. 2006 Nov;12(6):673-83. https://doi.org/10.1093/humupd/dml036
19. Hollinrake E, Abreu A, Maifeld M, Van Voorhis BJ, Dokras A. Increased risk of depressive disorders in women with polycystic ovary syndrome. Fertility and sterility. 2007 Jun 1;87(6):1369-76. https://doi.org/10.1016/j.fertnstert.2006.11.039
20. Veltman-Verhulst SM, Boivin J, Eijkemans MJ, Fauser BJ. Emotional distress is a common risk in women with polycystic ovary syndrome: a systematic review and meta-analysis of 28 studies. Human reproduction update. 2012 Nov 1;18(6):638-51. https://doi.org/10.1093/humupd/dms029
21. Gul S, Zahid SA, Ansari A. PCOS: symptoms and awareness in urban Pakistani women. Int J Pharma Res Health Sci. 2014 Oct;2(5):356-60. Available online at www.pharmahealthsciences.net
22. Mohamed HA. Effect of educational program on the level of knowledge regarding polycystic ovarian syndrome among adolescent girls. Journal of Nursing Education and Practice. 2016 Jun 3;6(10):80-7. Available from: https://nursingdidactics.com/index.php/ijnd/article/view/1746
23. Chinedu IA, Chukwuemeka OE, Ndumnworo OD, Kalu AU, Victor O. Effect of Short-Term Exposure to Formalin on Male Reproductive Hormones of Students in Nnewi. IOSR Journal of Dental and Medical Sciences. 2017;16:33-6. http://dx.doi.org/10.9790/0853-1611063336
24. Kareem AJ, Owa JA, Elusiyan JB. Estimations of total serum testosterone levels in Nigerian term neonates at birth using anogenital distance measurements. Journal of Pediatric Endocrinology and Metabolism. 2020 May 26;33(5):631-8. https://doi.org/10.1515/jpem-2019-0516
25. María R, Shirley M, Xavier C, Jaime S, David V, Rosa S, Jodie D. Preliminary phytochemical screening, total phenolic content and antibacterial activity of thirteen native species from Guayas province Ecuador. Journal of King Saud University-Science. 2018 Oct 1;30(4):500-5. https://doi.org/10.1016/j.jksus.2017.03.009
26. Ihim, AC., Nwosu, D.C., Nwanjo, H.U., Onyenekwe CC., Nnodim Johnkennedy, Manafa PO. Okeke A.C., Oluboyo A.O., Nobodo E.I.,Nwadike, C.Oze. Antilipid peroxidative and hypolipidaemic potentials on oxidative stress. Asian Journal of Pharmaceutical and Biological Research 2013; 3,18-23
27. Stalikas CD. Extraction, separation, and detection methods for phenolic acids and flavonoids. Journal of separation science. 2007 Dec;30(18):3268-95. https://doi.org/10.1002/jssc.200700261
28. Vause TD, Cheung AP, Sierra S, Claman P, Graham J, Guillemin JA, Lapensée L, Steward S, Wong BC. Ovulation induction in polycystic ovary syndrome. Journal of Obstetrics and Gynaecology Canada. 2010 May 1;32(5):495-502. https://doi.org/10.1016/S1701-2163(16)34504-2
29. OLUJIMI FO. Regulation of Reproductive Disorders Associated with Letrozole-Induced Polycystic Ovarian Syndrome in Rats by Ethanolic Extract of Parquetina nigrescens (Afzel.) Leaves.
30. Benjamin JJ, K M, Koshy T, KN M. DHEA and polycystic ovarian syndrome: Meta-analysis of case-control studies. PLoS One. 2021 Dec 21;16(12):e0261552. https://doi.org/10.1371/journal.pone.0261552
31. Hassan SM, al-Jaf AN, Hussien YA, Awad SM, Hadi NR. The potential antiviral activity of a novel pyrimidine derivative against Herpes Simplex Virus type-1 (HSV-1). Rev. Pharm. 2020 Feb;11:795-806.
32. Robinson S, Rodin DA, Deacon A, Wheeler MJ, Clayton RN. Which hormone tests for the diagnosis of polycystic ovary syndrome?. BJOG: An International Journal of Obstetrics & Gynaecology. 1992 Mar;99(3):232-8. https://doi.org/10.1111/j.1471-0528.1992.tb14505.x
33. Abbas, A.N., Al-Masaoodi, R.A., Hassan, S. and Al-Shemery, M.K., 2023. The relationship between hormonal levels and hematological parameters in cystic ovarian syndrome. Journal of Medicine and Life, 16(6), p.937. https://doi.org/10.25122%2Fjml-2022-0315
34. Richard SL, Ricardo A. Androgen excess disorders. Danforth’s Obstetrics and Gynecology.
35. Gonzalez F, Sia CL, Shepard MK, Rote NS, Minium J. Hyperglycemia-induced oxidative stress is independent of excess abdominal adiposity in normal-weight women with polycystic ovary syndrome. Human reproduction. 2012 Dec 1;27(12):3560-8. https://doi.org/10.1093/humrep/des320
36. Lim SS, Davies MJ, Norman RJ, Moran LJ. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Human reproduction update. 2012 Nov 1;18(6):618-37. https://doi.org/10.1093/humupd/dms030
37. Papalou O, M Victor V, Diamanti-Kandarakis E. Oxidative stress in polycystic ovary syndrome. Current pharmaceutical design. 2016 May 1;22(18):2709-22.
38. Vilmann LS, Thisted E, Baker JL, Holm JC. Development of obesity and polycystic ovary syndrome in adolescents. Hormone research in pediatrics. 2013 Nov 28;78(5-6):269-78. https://doi.org/10.1159/000345310
39. Blair SA, Kyaw-Tun T, Young IS, Phelan NA, Gibney J, McEneny J. Oxidative stress and inflammation in lean and obese subjects with polycystic ovary syndrome. The Journal of Reproductive Medicine. 2013 Mar 1;58(3-4):107-14.
40. Hilali N, Vural M, Camuzcuoglu H, Camuzcuoglu A, Aksoy N. Increased prolidase activity and oxidative stress in PCOS. Clinical endocrinology. 2013 Jul;79(1):105-10. https://doi.org/10.1111/cen.12110
41. Desai V, Prasad NR, Manohar SM, Sachan A, Narasimha SR, Bitla AR. Oxidative stress in non-obese women with polycystic ovarian syndrome. Journal of clinical and diagnostic research: JCDR. 2014 Jul;8(7):CC01. https://doi.org/10.7860%2FJCDR%2F2014%2F8125.4530
42. Zuo T, Zhu M, Xu W. Roles of oxidative stress in polycystic ovary syndrome and cancers. Oxidative medicine and cellular longevity. 2016 Oct;2016. https://doi.org/10.1155/2016/8589318
43. Fatima Q, Amin S, Kawa IA, Jeelani H, Manzoor S, Rizvi SM, Rashid F. Evaluation of antioxidant defense markers about hormonal and insulin parameters in women with polycystic ovary syndrome (PCOS): a case-control study. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2019 May 1;13(3):1957-61. https://doi.org/10.1016/j.dsx.2019.04.032
44. Sandhu JK, Waqar A, Jain A, Joseph C, Srivastava K, Ochuba O, Alkayyali T, Ruo SW, Poudel S. Oxidative stress in polycystic ovarian syndrome and the effect of antioxidant N-acetylcysteine on ovulation and pregnancy rate. Cureus. 2021 Sep 11;13(9). https://doi.org/10.7759/cureus.17887
45. Cheng X, He B. Clinical and biochemical potential of antioxidants in treating polycystic ovary syndrome. International Journal of Women's Health. 2022 Apr 1:467-79. https://doi.org/10.2147/IJWH.S345853
46. Kanafchian M, Esmaeilzadeh S, Mahjoub S, Rahsepar M, Ghasemi M. Status of serum copper, magnesium, and total antioxidant capacity in patients with polycystic ovary syndrome. Biological trace element research. 2020 Jan;193:111-7. https://doi.org/10.1007/s12011-019-01705-7
47. Uçkan K, Demir H, Turan K, Sarıkaya E, Demir C. Role of oxidative stress in obese and nonobese PCOS patients. International journal of clinical practice. 2022 Oct;2022. https://doi.org/10.1155/2022/4579831
Crossmark
Statistics
35 Views | 7 Downloads
How to Cite
1.
Ihim AC, Onyenekwe CC, Eze NN, Obi PC, Osakue N, Awalu J, Ikwelle TA. Evaluation of Some Hormones Total Antioxidant Capacity and Malondialdehyde Levels in Polycystic Ovarian Syndrome Women attending the gynecology Clinic at Nnewi. JDDT [Internet]. 15May2024 [cited 17May2024];14(5):108-12. Available from: https://jddtonline.info/index.php/jddt/article/view/6539